Obiltoxaximab

Kathryn Dzintars, PharmD, BCPS

INDICATIONS

FDA

  • Treatment of inhalational anthrax due to Bacillus anthracis (in combination with antibacterial drugs)
  • Prevention of inhalational anthrax when alternative agents are unavailable

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: June 1, 2016